Recruiting studies: Early Stage Estrogen Receptor Er Positive Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2-
Phase 3 · 1 location(s) · Genentech, Inc. · NCT07541079 NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Phase 2 · 8 location(s) · Swiss Cancer Institute · NCT06452394 A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth
Phase 2 · 78 location(s) · Eli Lilly and Company · NCT07287098 Active Surveillance in Older Women With ER+ Breast Cancer
Phase N/A · 1 location(s) · University of Pittsburgh · NCT07262138 Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Phase 2 · 2 location(s) · Baylor Breast Care Center · NCT05020860 Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06500208 Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)
Phase 2 · 1 location(s) · Jules Bordet Institute · NCT06150898 A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High
Phase 3 · 555 location(s) · Stemline Therapeutics, Inc. · NCT06492616

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.